Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2016 (2016), Article ID 2312078, 4 pages
http://dx.doi.org/10.1155/2016/2312078
Case Report

Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism

1Department of Internal Medicine and Division of Cardiology, New York Methodist Hospital, Brooklyn, NY 11215, USA
2Surat Municipal Institute of Medical Education and Research, Umarwada, Surat, Gujarat 395010, India
3Department of Cardiology, Guthrie Clinic, Sayre, PA 18840, USA

Received 16 April 2016; Accepted 5 July 2016

Academic Editor: Michael S. Firstenberg

Copyright © 2016 Ashwad Afzal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. Bertrand, H.-J. Rupprecht, P. Urban, and A. H. Gershlick, “Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS),” Circulation, vol. 102, no. 6, pp. 624–629, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. S. R. Mehta, S. Yusuf, R. J. G. Peters et al., “Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study,” The Lancet, vol. 358, no. 9281, pp. 527–533, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Savi, J. M. Herbert, A. M. Pflieger et al., “Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel,” Biochemical Pharmacology, vol. 44, no. 3, pp. 527–532, 1992. View at Publisher · View at Google Scholar · View at Scopus
  4. J. L. Mega, S. L. Close, S. D. Wiviott et al., “Cytochrome P-450 polymorphisms and response to clopidogrel,” The New England Journal of Medicine, vol. 360, no. 4, pp. 354–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-S. Hulot, A. Bura, E. Villard et al., “Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects,” Blood, vol. 108, no. 7, pp. 2244–2247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Umemura, T. Furuta, and K. Kondo, “The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects,” Journal of Thrombosis and Haemostasis, vol. 6, no. 8, pp. 1439–1441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Desta, X. Zhao, J.-G. Shin, and D. A. Flockhart, “Clinical significance of the cytochrome P450 2C19 genetic polymorphism,” Clinical Pharmacokinetics, vol. 41, no. 12, pp. 913–958, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. M. F. de Morais, G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer, and J. A. Goldstein, “The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans,” The Journal of Biological Chemistry, vol. 269, no. 22, pp. 15419–15422, 1994. View at Google Scholar · View at Scopus
  9. J. T. Brandt, S. L. Close, S. J. Iturria et al., “Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel,” Journal of Thrombosis and Haemostasis, vol. 5, no. 12, pp. 2429–2436, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-P. Collet, J.-S. Hulot, G. Anzaha et al., “High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2),” JACC: Cardiovascular Interventions, vol. 4, no. 4, pp. 392–402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. R. F. Storey, S. Husted, R. A. Harrington et al., “Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes,” Journal of the American College of Cardiology, vol. 50, no. 19, pp. 1852–1856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Wallentin, R. C. Becker, A. Budaj et al., “Ticagrelor versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 361, no. 11, pp. 1045–1057, 2009. View at Publisher · View at Google Scholar · View at Scopus